Zafgen Inc (ZFGN):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7568)
◆英語タイトル:Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7568
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:57
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Zafgen Inc (Zafgen) is a clinical-stage biopharmaceutical company that develops transformative therapies for patients affected by a range of metabolic diseases. Its pipeline product portfolio includes ZGN-1061, a small molecule MetAP2 inhibitor being developed for patients with type 2 diabetes; ZGN-1258 is designed to change the way the body metabolizes fat, reduce fat mass, and decrease hyperphagia, for the treatment of Prader-Willi syndrome (PWS). Zafgen has developed several MetAP2 inhibitors, which modulate the cellular mechanisms that control the body’s ability to make and store fat and glucose. The company operates through academic institutions, other companies and research organizations for the development of therapeutic drugs against rare complex metabolic disorders. Zafgen is headquartered in Boston, Massachusetts, the US.

Zafgen Inc (ZFGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zafgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zafgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zafgen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Zafgen Raises US$45 Million In Series E Financing Round 11
Zafgen Raises US$21 Million In Series D Financing 13
Zafgen Raises US$3 Million In Venture Financing 15
Partnerships 16
ZappRx Enters into Agreement with Zafgen 16
Equity Offering 17
Zafgen Raises USD69 Million in Public Offering of Shares 17
Zafgen Raises USD138 Million in Public Offering of Shares 19
Zafgen Raises USD110.4 Million in IPO 21
Zafgen Inc – Key Competitors 23
Zafgen Inc – Key Employees 24
Zafgen Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 07, 2018: Zafgen announces second quarter 2018 financial results 26
May 08, 2018: Zafgen Announces First Quarter 2018 Financial Results 29
Mar 06, 2018: Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results 31
Nov 07, 2017: Zafgen Reports Third Quarter 2017 Financial Results 33
Aug 08, 2017: Zafgen Reports Second Quarter 2017 Financial Results 35
May 09, 2017: Zafgen Reports First Quarter 2017 Financial Results 37
Mar 09, 2017: Zafgen Reports Fourth Quarter And Full Year 2016 Financial Results 38
Corporate Communications 39
Aug 02, 2018: Zafgen announces departure of President and Chief Scientific Officer Dr. Thomas Hughes 39
Jun 25, 2018: Zafgen set to join Russell 3000 index 40
Jun 07, 2018: Zafgen Appoints Industry Veteran And Healthcare Policy Expert Dr. Wendy Everett To Its Board Of Directors 41
May 30, 2018: Zafgen Appoints Brian Mcveigh As Chief Business Officer 42
Oct 10, 2017: Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer 43
Clinical Trials 44
Jun 25, 2018: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call 44
Jun 23, 2018: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes 45
Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes 47
Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061 48
Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes 49
Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes 50
Jun 10, 2017: Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions 51
Jun 06, 2017: Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions 53
May 04, 2017: Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor 54
Mar 09, 2017: Zafgen Provides Update on ZGN-1061 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Zafgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zafgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zafgen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Zafgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zafgen Raises US$45 Million In Series E Financing Round 11
Zafgen Raises US$21 Million In Series D Financing 13
Zafgen Raises US$3 Million In Venture Financing 15
ZappRx Enters into Agreement with Zafgen 16
Zafgen Raises USD69 Million in Public Offering of Shares 17
Zafgen Raises USD138 Million in Public Offering of Shares 19
Zafgen Raises USD110.4 Million in IPO 21
Zafgen Inc, Key Competitors 23
Zafgen Inc, Key Employees 24
Zafgen Inc, Other Locations 25

List of Figures
Zafgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zafgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Zafgen Inc (ZFGN):製薬・医療:M&Aディール及び事業提携情報(Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆